Feasibility of Resting Intervals During Exercise Programs for Individuals With Knee Osteoarthritis (CaRE)

February 4, 2026 updated by: Sara R. Piva, University of Pittsburgh

Mechanical and Molecular Determinants of Cartilage Response to Exercise

This pilot randomize trial tests the feasibility of administering two different exercise programs in people with knee osteoarthritis. One group receives the exercise program administered as usual, and the other group received the exercise program with resting intervals.

Study Overview

Detailed Description

Participants will be randomly assigned to 1 of 2 treatment groups. Both groups do the same exercise program 3 times a week for 12 weeks on nonconsecutive days. The only difference is that one group will perform the exercises with small resting periods between exercises as normally done in clinical practice. The other group will have two long rests of 45 minutes during the exercise training session. Before and after the exercise programs, participants will undergo a series of assessments including gait analysis, MRI imaging of knees, tests of muscle strength and physical performance. Questionnaires will be completed. Blood and synovial fluid will be collected as part of this study.

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15213
        • Recruiting
        • University of Pittsburgh
        • Contact:
          • Sara R Piva, PhD, PT, FAPTA
          • Phone Number: 412-383-6712
          • Email: spiva@pitt.edu
        • Principal Investigator:
          • Sara R Piva, PhD, PT, FAPTA

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age between 45 and 79 yo.
  • Clinical diagnosis of primary, early to moderate stage knee osteoarthritis.
  • BMI range < 35 kg/m2.
  • Sedentary lifestyle
  • Knee joint is the most painful joint in the body.
  • Ability to speak and understand English.
  • Willingness to comply with all study procedures and be available for the duration of the study.

Exclusion Criteria:

  • Non-OA disease of the knee.
  • Advanced knee osteoarthritis
  • Knee injection in the past 3 months.
  • Major knee trauma/surgery in the past 5 years or previous knee surgery with hardware limiting cartilage assessment..
  • Participate in regular exercise or physical activity .
  • Participation in an intervention study for knee OA.
  • Currently using a cane, walker or crutches to walk.
  • History of cardiovascular disease or hypertension not controlled by medication.
  • Two or more unexplained falls in the past year.
  • Inflammatory, autoimmune disorders, neurological, systemic, muscular, or connective tissue conditions that affect walking or ability to exercise.
  • Contraindication to MRI.
  • Medical condition or characteristic of the participant that could place the individual at increased risk or preclude s/he from complying with study procedures.
  • Pregnant female.
  • Acute or terminal illness.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Exercise With Rest
Participants in this arm exercise 3 times a week for 12 weeks. Exercise program consists of warm-up, strengthening exercises of the lower major extremity muscle groups, and aerobic training using a treadmill. These sessions include two 45 minute rest periods between exercises and take about two and a half hours.
Participants in this arm exercise 3 times a week for 12 weeks. Exercise program consists of warm-up, strengthening exercises of the lower major extremity muscle groups, and aerobic training using a treadmill. These sessions include two 45 minute rest periods between exercises and take about two and a half hours.
Active Comparator: Exercise Without Rest
Exercise without Rest
Participants in this arm exercise 3 times a week for 12 weeks. Exercise program consists of warm-up, strengthening exercises of the lower major extremity muscle groups, and aerobic training using a treadmill. These sessions include minimal resting periods between exercises and take about one hour.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility of recruitment
Time Frame: The time frame for this outcome is from the enrollment period up to randomization. This outcome measure is independent of treatment assignment.
The number of eligible individuals who are randomized out of all eligible individuals.
The time frame for this outcome is from the enrollment period up to randomization. This outcome measure is independent of treatment assignment.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety of interventions
Time Frame: 3 months (window of 1 month)
The number of adverse events related to study participation in each arm
3 months (window of 1 month)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adherence to Intervention
Time Frame: 3 months (window of 1 month)
The number of intervention sessions attended out of the total number of intervention sessions prescribed in the study.
3 months (window of 1 month)
Study retention
Time Frame: 3 months (window of 1 month)
The number of participants in each intervention arm who attend the follow-up assessment visit out of the number of participants randomized to each intervention arm.
3 months (window of 1 month)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sara Piva, University of Pittsburgh

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 4, 2024

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

January 17, 2025

First Submitted That Met QC Criteria

February 26, 2025

First Posted (Actual)

March 4, 2025

Study Record Updates

Last Update Posted (Actual)

February 9, 2026

Last Update Submitted That Met QC Criteria

February 4, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The data supporting the conclusions of this study will be available upon request to the principal investigators. The data will include participants demographic and biomedical information, along with primary and secondary outcome measures. The data dictionary will be provided.

IPD Sharing Time Frame

The data will be available at the time of the publication of the pilot feasibility results in peer-reviewed medical journal.

IPD Sharing Access Criteria

IPD will be available upon request to the principal investigators. The data will include participants demographic and biomedical information, along with primary and secondary outcome measures. The data dictionary will be provided. Non-identifiable data will be shared in CSV files.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe